Adjunct Research Scientist
Internal Medicine
[email protected]
Available to mentor
Paul Kirchhoff
Adjunct Assistant Research Scientist
-
Kaneshige A, Yang Y, Bai L, Wang M, Xu R, Mallik L, Chinnaswamy K, Metwally H, Wang Y, McEachern D, Tošović J, Yang C-Y, Kirchhoff PD, Meagher JL, Stuckey JA, Wang S. J Med Chem, 2024 Sep 23;Journal ArticleDiscovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader.
DOI:10.1021/acs.jmedchem.4c01009 PMID: 39311434 -
Xiang W, Zhao L, Han X, Xu T, Kregel S, Wang M, Miao B, Qin C, Wang M, McEachern D, Lu J, Bai L, Yang C-Y, Kirchhoff PD, Takyi-Williams J, Wang L, Wen B, Sun D, Ator M, Mckean R, Chinnaiyan AM, Wang S. J Med Chem, 2023 Sep 28; 66 (18): 13280 - 13303.Journal ArticleDiscovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
DOI:10.1021/acs.jmedchem.3c01264 PMID: 37683104 -
Han X, Zhao L, Xiang W, Miao B, Qin C, Wang M, Xu T, McEachern D, Lu J, Wang Y, Metwally H, Yang C-Y, Kirchhoff PD, Wang L, Matvekas A, Takyi-Williams J, Wen B, Sun D, Ator M, Mckean R, Wang S. J Med Chem, 2023 Jul 13; 66 (13): 8822 - 8843.Journal ArticleDiscovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
DOI:10.1021/acs.jmedchem.3c00405 PMID: 37382562 -
Kaneshige A, Bai L, Wang M, McEachern D, Meagher JL, Xu R, Wang Y, Jiang W, Metwally H, Kirchhoff PD, Zhao L, Jiang H, Wang M, Wen B, Sun D, Stuckey JA, Wang S. Nat Chem Biol, 2023 Jun; 19 (6): 703 - 711.Journal ArticleA selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo.
DOI:10.1038/s41589-022-01248-4 PMID: 36732620 -
Kaneshige A, Bai L, Wang M, McEachern D, Meagher JL, Xu R, Kirchhoff PD, Wen B, Sun D, Stuckey JA, Wang S. J Med Chem, 2023 Feb 23; 66 (4): 2717 - 2743.Journal ArticleDiscovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.
DOI:10.1021/acs.jmedchem.2c01665 PMID: 36735833 -
Xiang W, Zhao L, Han X, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Kirchhoff PD, Wang L, Matvekas A, He M, Wen B, Sun D, Wang S. J Med Chem, 2021 Sep 23; 64 (18): 13487 - 13509.Journal ArticleDiscovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
DOI:10.1021/acs.jmedchem.1c00900 PMID: 34473519 -
Zhang M, Aguilar A, Xu S, Huang L, Chinnaswamy K, Sleger T, Wang B, Gross S, Nicolay BN, Ronseaux S, Harvey K, Wang Y, McEachern D, Kirchhoff PD, Liu Z, Stuckey J, Tron AE, Liu T, Wang S. J Med Chem, 2021 Jul 22; 64 (14): 10333 - 10349.Journal ArticleDiscovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.
DOI:10.1021/acs.jmedchem.1c00789 PMID: 34196551 -
Zwicker JD, Diaz NA, Guerra AJ, Kirchhoff PD, Wen B, Sun D, Carruthers VB, Larsen SD. Bioorg Med Chem Lett, 2018 Jun 1; 28 (10): 1972 - 1980.Journal ArticleOptimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability.
DOI:10.1016/j.bmcl.2018.03.020 PMID: 29650289
